Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 8/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | CASP4 | P49662 | 1/20 | 0.31 |
| ▸ | CASP5 | P51878 | 1/20 | 0.31 |
| ▸ | CASP9 | P55211 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.31 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 2/20 | 0.30 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5177734 | 0.93 | ENPEP (0.32) | PSENENCTSDCASP1CASP3CASP4 | |
| SCHEMBL6269573 | 0.81 | — | — | |
| SCHEMBL5178281 | 0.81 | CTSB (0.32) | PSENENCTSDRENCASP1CASP3 | |
| SCHEMBL30544517 | 0.80 | PSENEN (0.47) | PSENENCTSDRENCASP1CASP3 | |
| SCHEMBL30544518 | 0.80 | PSENEN (0.47) | PSENENCTSDRENCASP1CASP3 | |
| SCHEMBL7613501 | 0.69 | PSENEN (0.55) | PSENENCTSDRENCASP1CASP3 | |
| SCHEMBL7613504 | 0.69 | PSENEN (0.55) | PSENENCTSDRENCASP1CASP3 | |
| SCHEMBL20338802 | 0.67 | HDAC6 (0.31) | — | |
| SCHEMBL20338800 | 0.67 | HDAC6 (0.31) | — | |
| SCHEMBL5176929 | 0.67 | CTSD (0.53) | PSENENCTSDRENCASP1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1602719-B1 | Control of transglutaminase catalyzed protein modification by selective irreversible transglutaminase inhibitors | N ZYME BIOTEC GMBH (DE) | 2007-06-06 | — | — | EP | claimed |
| EP-1602719-A1 | Control of transglutaminase catalyzed protein modification by selective irreversible transglutaminase inhibitors | N-Zyme BioTec GmbH (DE) | 2005-12-07 | — | — | EP | claimed |
| EP-1600504-A1 | Control of transglutaminase catalyzed protein modification by selective irreversible transglutaminase inhibitors | N-Zyme BioTec GmbH (DE) | 2005-11-30 | — | — | EP | claimed |
| EP-1602719-B1 | Control of transglutaminase catalyzed protein modification by selective irreversible transglutaminase inhibitors | N ZYME BIOTEC GMBH (DE) | 2007-06-06 | — | — | EP | disclosed |
| EP-1602719-A1 | Control of transglutaminase catalyzed protein modification by selective irreversible transglutaminase inhibitors | N-Zyme BioTec GmbH (DE) | 2005-12-07 | — | — | EP | disclosed |
| EP-1600504-A1 | Control of transglutaminase catalyzed protein modification by selective irreversible transglutaminase inhibitors | N-Zyme BioTec GmbH (DE) | 2005-11-30 | — | — | EP | disclosed |